The 10-second takeaway
For the quarter ended Sep. 30 (Q3), CVS Caremark met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share increased significantly.
Gross margins contracted, operating margins expanded, net margins were steady.
CVS Caremark chalked up revenue of $30.23 billion. The 19 analysts polled by S&P Capital IQ predicted revenue of $30.09 billion on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $26.67 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.85. The 21 earnings estimates compiled by S&P Capital IQ averaged $0.84 per share. GAAP EPS of $0.79 for Q3 were 22% higher than the prior-year quarter's $0.65 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 18.7%, 70 basis points worse than the prior-year quarter. Operating margin was 6.0%, 10 basis points better than the prior-year quarter. Net margin was 3.3%, about the same as the prior-year quarter.
Next quarter's average estimate for revenue is $31.29 billion. On the bottom line, the average EPS estimate is $1.08.
Next year's average estimate for revenue is $122.84 billion. The average EPS estimate is $3.37.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,669 members out of 1,733 rating the stock outperform, and 64 members rating it underperform. Among 424 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 412 give CVS Caremark a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CVS Caremark is outperform, with an average price target of $52.36.
If you're interested in retailers like CVS Caremark as investments, you should check out the retail concept that is The Motley Fool's top stock for 2012. Its founder wrote the book on big box retailing, and it's growing in increasingly important international markets. Click here for instant access to this free report.
- Add CVS Caremark to My Watchlist.